Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iminostilbene SCHEMBL29926907 | 0.82 | MAPT (1.00) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| Iminostilbene SCHEMBL75288 | 0.82 | MAPT (1.00) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| Iminostilbene SCHEMBL5063042 | 0.79 | MAPT (0.94) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| Iminostilbene SCHEMBL9685179 | 0.79 | MAPT (0.94) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL11163331 | 0.77 | MAPT (0.62) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| Bromide SCHEMBL11163154 | 0.76 | MAPT (0.60) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL272082 | 0.71 | MAPT (0.68) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL10449074 | 0.71 | MAPT (0.68) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL10448842 | 0.71 | MAPT (0.68) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL29870379 | 0.71 | MAPT (0.68) | MAPTGAARAB9ASMN1; SMN2P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732227-B2 | Modified colorants and inkjet ink compositions comprising modified colorants | CABOT CORPORATION (US) | 2017-08-15 | — | — | US | claimed |
| US-20160075880-A1 | Modified Colorants and Inkjet Ink Compositions Comprising Modified Colorants | CABOT CORPORATION | 2016-03-17 | — | — | US | claimed |
| US-7728136-B2 | Such as 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one via coupling piperazine derivative with alkyl halide by heating in solvent free conditions | LUPIN LIMITED (IN) | 2010-06-01 | — | — | US | claimed |
| JP-2009515007-A | — | — | 2009-04-09 | — | — | JP | claimed |
| JP-2009513802-A | — | — | 2009-04-02 | — | — | JP | claimed |
| EP-1951821-A2 | MODIFIED COLORANTS AND INKJET INK COMPOSITIONS COMPRISING MODIFIED COLORANTS | Cabot Corporation (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1951819-A2 | MODIFIED COLORANTS AND INKJET INK COMPOSITIONS COMPRISING MODIFIED COLORANTS | Cabot Corporation (US) | 2008-08-06 | — | — | EP | claimed |
| US-20070238877-A1 | Novel Method for the Preparation of Aryl Piperazinyl-Heterocyclic Compounds | LUPIN LIMITED (IN) | 2007-10-11 | — | — | US | claimed |
| WO-2007053563-A2 | MODIFIED COLORANTS AND INKJET INK COMPOSITIONS COMPRISING MODIFIED COLORANTS | CABOT CORPORATION (US) | 2007-05-10 | — | — | WO | claimed |
| WO-2007053564-A2 | MODIFIED COLORANTS AND INKJET INK COMPOSITIONS COMPRISING MODIFIED COLORANTS | CABOT CORPORATION (US) | 2007-05-10 | — | — | WO | claimed |
| US-5338846-A | Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt | PFIZER INC. (US) | 1994-08-16 | — | — | US | claimed |
| EP-0584903-A1 | Process for preparing aryl piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1994-03-02 | — | — | EP | claimed |
| US-5206366-A | Process for preparing aryl piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1993-04-27 | — | — | US | claimed |
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | claimed |
| EP-0229947-B1 | NOVEL CRYSTALLINE SALTS OF ARYLOXY-PROPANOLAMINES, THEIR PREPARATION AND THEIR USE | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1991-03-13 | — | — | EP | claimed |
| US-4883795-A | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1989-11-28 | — | — | US | claimed |
| EP-0159962-B1 | FIBRE-REACTIVE CHROMIUM OR COBALT COMPLEXES, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1989-02-08 | — | — | EP | claimed |
| EP-0281309-A1 | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1988-09-07 | — | — | EP | claimed |
| US-4680385-A | Metal dye complexes containing an azo or azomethine dye and a colorless ligand with the C═N--N═C group | CIBA-GEIGY CORPORATION (US) | 1987-07-14 | — | — | US | claimed |
| US-4678851-A | FIBER-RACTIVE | CIBA-GEIGY CORPORATION (US) | 1987-07-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238877-A1 | Novel Method for the Preparation of Aryl Piperazinyl-Heterocyclic Compounds | AQP1, AQP3, AQP4 | MAPT 3943/4885GAA 539/4885RAB9A 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.